Radiochemical Feasibility of Mixing of Tc-MAA and Y-Microspheres with Omnipaque Contrast.

Yttrium-90 (Y) microspheres are widely used for the treatment of liver-dominant malignant tumors. They are infused via catheter into the hepatic artery branches supplying the tumor under fluoroscopic guidance based on pre-therapy angiography and Technetium-99m macroaggregated albumin (Tc-MAA) planning. However, at present, these microspheres are suspended in radiolucent media such as dextrose 5% (D5) solution.

Push-pull type meso-ester substituted BODIPY near-infrared dyes as contrast agents for photoacoustic imaging.

A series of push-pull type meso-ester substituted BODIPY dyes 1-4 with intense near-infrared absorption, largely enhanced photoacoustic (PA) activity and excellent photo-stability were synthesized. The impact of the electronic structure on the PA activity was also discussed. Moreover, the in vitro and in vivo PA imaging were investigated, which suggested a passive targeting capacity in the tumor site.

Naphthalene-fused BODIPY near-infrared dye as a stable contrast agent for in vivo photoacoustic imaging.

Photoacoustic imaging (PAI) has emerged as an advantageous modality with high resolution and deep tissue penetration. However, its application is limited by the lack of available contrast agents. In this work, we report the synthesis of a naphthalene fused BODIPY dimer Na-BD, and the impact of the electronic structure on the oxidative cyclo-dehydrogenation process was systematically studied.

Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice.

Purpose: 32P BioSilicon is a new, implantable, radiological medical device that comprises particles of highly pure silicon encapsulating 32phosphorus (32P) for the treatment of unresectable solid tumors. Prior to administration, the device particles are suspended in a formulant which provides an even suspension of the intended dose for implantation. The primary objective of this animal trial study was to investigate the effects of intratumoral injection of 32)P BioSilicon on human hepatocellular (HepG2) and pancreatic carcinoma (2119) xenografts implanted in nude mice (BALB/c).